PortfoliosLab logoPortfoliosLab logo
CRBP vs. CADL
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CRBP vs. CADL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Candel Therapeutics, Inc. (CADL). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CRBP achieves a 10.20% return, which is significantly lower than CADL's 77.17% return.


CRBP

1D
-0.88%
1M
-3.03%
6M
8.46%
YTD
10.20%
1Y
-3.65%
3Y*
7.40%
5Y*
-26.25%
10Y*
-20.07%
ALL TIME*
-17.86%

CADL

1D
1.42%
1M
1.83%
6M
71.40%
YTD
77.17%
1Y
59.14%
3Y*
112.04%
5Y*
5.69%
10Y*
ALL TIME*
4.58%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$11.11M$12.79M$17.21M
$2.30M$2.68M$4.28M

CRBP vs. CADL - Yearly Performance Comparison


2026 (YTD)20252024202320222021
CRBP
Corbus Pharmaceuticals Holdings, Inc.
10.20%-31.02%95.36%82.20%-82.05%-55.71%
CADL
Candel Therapeutics, Inc.
77.17%-34.91%490.48%-17.88%-77.11%-2.25%

Correlation

The correlation between CRBP and CADL is 0.34, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.34

Correlation (3Y)
Balances recent behavior with more history.

0.23

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.18

Correlation (All Time)
Calculated using the full available price history since Jul 27, 2021

0.18

The correlation between CRBP and CADL shifts across timeframes, from 0.18 (all time) to 0.34 (1 year), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

CRBP:

$166.19M

CADL:

$733.43M

EPS

CRBP:

-$5.72

CADL:

-$0.95

PB Ratio

CRBP:

1.33

CADL:

4.52

Total Revenue (TTM)

CRBP:

$0.00

CADL:

$0.00

Gross Profit (TTM)

CRBP:

-$149.00K

CADL:

-$600.00K

EBITDA (TTM)

CRBP:

-$61.36M

CADL:

-$71.64M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CRBP vs. CADL — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CRBP
CRBP Risk / Return Rank: 4444
Overall Rank
CRBP Sharpe Ratio Rank: 4242
Sharpe Ratio Rank
CRBP Sortino Ratio Rank: 4646
Sortino Ratio Rank
CRBP Omega Ratio Rank: 4848
Omega Ratio Rank
CRBP Calmar Ratio Rank: 4343
Calmar Ratio Rank
CRBP Martin Ratio Rank: 4343
Martin Ratio Rank

CADL
CADL Risk / Return Rank: 7272
Overall Rank
CADL Sharpe Ratio Rank: 7070
Sharpe Ratio Rank
CADL Sortino Ratio Rank: 7171
Sortino Ratio Rank
CADL Omega Ratio Rank: 6969
Omega Ratio Rank
CADL Calmar Ratio Rank: 7676
Calmar Ratio Rank
CADL Martin Ratio Rank: 7373
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CRBP vs. CADL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Corbus Pharmaceuticals Holdings, Inc. (CRBP) and Candel Therapeutics, Inc. (CADL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CRBPCADLDifference
Sharpe ratioReturn per unit of total volatility

-0.82

Sortino ratioReturn per unit of downside risk

-1.04

Omega ratioGain probability vs. loss probability

1.07

1.19

-0.11

Calmar ratioReturn relative to maximum drawdown

-0.05

1.71

-1.76

Martin ratioReturn relative to average drawdown

-0.07

3.42

-3.50

CRBP vs. CADL - Sharpe Ratio Comparison

The current CRBP Sharpe Ratio is -0.04, which is lower than the CADL Sharpe Ratio of 0.78. The chart below compares the historical Sharpe Ratios of CRBP and CADL, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CRBP vs. CADL - Drawdown Comparison

The maximum CRBP drawdown since its inception was -99.31%, which is greater than CADL's maximum drawdown of -94.33%. Use the drawdown chart below to compare losses from any high point for CRBP and CADL.


Loading charts...

Drawdown Indicators


CRBPCADLDifference

Max Drawdown

Largest peak-to-trough decline

-99.31%

-94.33%

-4.98%

Max Drawdown (1Y)

Largest decline over 1 year

-61.88%

-32.52%

-29.36%

Max Drawdown (3Y)

Largest decline over 3 years

-92.01%

-72.86%

-19.15%

Max Drawdown (5Y)

Largest decline over 5 years

-94.87%

-94.33%

-0.54%

Max Drawdown (10Y)

Largest decline over 10 years

-99.31%

Current Drawdown

Current decline from peak

-97.11%

-28.50%

-68.61%

Average Drawdown

Average peak-to-trough decline

-66.40%

-61.85%

-4.55%

Ulcer Index

Depth and duration of drawdowns from previous peaks

45.40%

16.30%

+29.10%

Volatility

CRBP vs. CADL - Volatility Comparison

The current volatility for Corbus Pharmaceuticals Holdings, Inc. (CRBP) is 11.86%, while Candel Therapeutics, Inc. (CADL) has a volatility of 16.17%. This indicates that CRBP experiences smaller price fluctuations and is considered to be less risky than CADL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CRBPCADLDifference

Volatility (1M)

Calculated over the trailing 1-month period

11.86%

16.17%

-4.31%

Volatility (6M)

Calculated over the trailing 6-month period

59.99%

51.93%

+8.06%

Volatility (1Y)

Calculated over the trailing 1-year period

79.24%

71.20%

+8.04%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

159.05%

165.08%

-6.03%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

129.03%

164.95%

-35.92%

Dividends

CRBP vs. CADL - Dividend Comparison

Neither CRBP nor CADL has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

CRBP vs. CADL - Financials Comparison

This section allows you to compare key financial metrics between Corbus Pharmaceuticals Holdings, Inc. and Candel Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

Frequently Asked Questions


CRBP and CADL have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CADL has higher volatility (16.17%) compared to CRBP (11.86%). In terms of maximum drawdown, CRBP dropped -99.31% vs CADL's -94.33%.

CADL currently has the higher Sharpe Ratio (0.78 vs -0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CRBP and CADL

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer